Executive Change: Stuart Therapeutics Inc. Appoints Dave LeCause as Senior Commercial Advisor

Stuart, FL – Stuart Therapeutics, Inc. has announced the appointment of Dave LeCause as Senior Commercial Advisor. About Stuart Therapeutics, Inc.: Stuart Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing a unique synthetic protein platform, called PolyCol, designed to target and repair disease damaged helical collagen in the human body. On its website, the company describes PolyCol as a series of synthesized amino acid or collagen mimetic peptide sequences that specifically bind to and repair damaged helical collagen in the extracellular matrix and in membranes, addressing a target that was previously considered undruggable. Stuart Therapeutics positions itself as a leader in ECM targeting therapeutics, using this platform to support tissue repair, restore homeostatic cell signaling, and reduce inflammation, particularly in ophthalmic and other collagen related disease settings. The company emphasizes the potential of its technology to enable rapid healing and functional restoration in diseased or injured tissues, highlighting its role in preserving patients future health and quality of life. Overall, Stuart Therapeutics, Inc. presents itself as an innovative life sciences developer advancing a novel, proprietary platform to treat conditions driven by collagen damage.

For more information visit: https://stuarttherapeutics.com/

Stuart Therapeutics, Inc.
411 Southeast Osceola Street Suite 203
Stuart, FL 34994
Phone: 772-678-7307
LinkedIn: https://www.linkedin.com/company/stuart-therapeutics/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved